Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 557,467 |
Reported balance
After 2026-09-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-09 · Sale · Disposed 523 · Balance 557,467 F1: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026. F3: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5: Shares held directly by MGC 2018 LP. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 624,765 |
Reported balance
After 2026-09-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-09 · Sale · Disposed 585 · Balance 624,765 F2: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026. F3: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6: Shares held directly by MGC 2018 QP. |
| Common StockSEC Table I · non-derivative | Direct | 9,077 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 9,077 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.
F2: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.
F3: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
F4: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
F5: Shares held directly by MGC 2018 LP.
F6: Shares held directly by MGC 2018 QP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 23:45 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 585 | $6.02 | $3,524.22 |
DisclosureSEC source: 0001193125-26-389545 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 624,765 F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 23:45 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 523 | $6.02 | $3,150.71 |
DisclosureSEC source: 0001193125-26-389545 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 557,467 F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 23:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 5,294 | $6.02 | $31,860.88 |
DisclosureSEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 625,350 F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 23:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 4,725 | $6.02 | $28,436.47 |
DisclosureSEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 557,990 F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 23:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 3,223 | $6.07 | $19,562.97 |
DisclosureSEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 630,644 F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 23:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,877 | $6.07 | $17,462.81 |
DisclosureSEC source: 0001193125-26-385511 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 562,715 F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:58 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 18,706 | $6.01 | $112,389.39 |
DisclosureSEC source: 0001193125-26-357225 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 633,867 F2 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:58 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 16,696 | $6.01 | $100,312.91 |
DisclosureSEC source: 0001193125-26-357225 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 565,592 F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026. F3 · price: Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein. F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:02 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120200 · ownership.xml · derivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:02 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120200 · ownership.xml · derivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:02 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 20,724 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120200 · ownership.xml · derivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:02 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 20,724 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120200 · ownership.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,724 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:29 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064103 · ownership.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 21:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 19,111 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-25-077073 · ownership.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 23:32 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 9,077 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139792 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,077 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 5,000 | $1.49 | $7,467.50 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 6 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 652,573 F9 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.46 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 5,000 | $1.49 | $7,462.00 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 5 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 582,288 F8 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.44 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 18,483 | $1.43 | $26,406.66 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 647,573 F7 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.41 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 12,289 | $1.43 | $17,576.96 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 577,288 F6 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.405 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 6,517 | $1.45 | $9,427.49 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 629,090 F4 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.435 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 01:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 12,711 | $1.45 | $18,367.40 |
DisclosureSEC source: 0000950170-24-135150 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 564,999 F1 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.40 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:07 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 25,000 | $1.42 | $35,417.50 |
DisclosureSEC source: 0000950170-24-131660 · ownership.xml · nonDerivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 622,573 F7 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.36 to $1.44 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:07 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 25,000 | $1.42 | $35,422.50 |
DisclosureSEC source: 0000950170-24-131660 · ownership.xml · nonDerivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 552,288 F6 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.36 to $1.44 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:07 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 12,500 | $1.39 | $17,427.50 |
DisclosureSEC source: 0000950170-24-131660 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 597,573 F4 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.38 to $1.409 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:07 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 12,500 | $1.39 | $17,417.50 |
DisclosureSEC source: 0000950170-24-131660 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 527,288 F1 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.3767 to $1.41 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 25,000 | $1.15 | $28,870.00 |
DisclosureSEC source: 0000950170-24-129830 · ownership.xml · nonDerivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 514,788 F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 25,000 | $1.16 | $29,000.00 |
DisclosureSEC source: 0000950170-24-129830 · ownership.xml · nonDerivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 585,073 F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 75,000 | $1.04 | $77,730.00 |
DisclosureSEC source: 0000950170-24-129830 · ownership.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 489,788 F4 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0293 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F5 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 75,000 | $1.03 | $77,527.50 |
DisclosureSEC source: 0000950170-24-129830 · ownership.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 560,073 F1 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0211 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F3 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 22:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 64,503 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076410 · ownership.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 22:03 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 719 | $21.91 | $15,753.29 |
DisclosureSEC source: 0001209191-24-001770 · doc4.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 485,073 F5 · kind: The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023. F6 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F7 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 22:03 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 706 | $21.92 | $15,475.52 |
DisclosureSEC source: 0001209191-24-001770 · doc4.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 414,788 F1 · kind: The reported sale of 706 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023. F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.96. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F4 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 22:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,800 | $21.92 | $39,456.00 |
DisclosureSEC source: 0001209191-24-001537 · doc4.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 485,792 F5 · kind: The reported sale of 1,800 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023. F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F6 · ownership.nature: Shares held directly by MGC 2018 QP. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 22:08 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,869 | $21.93 | $40,987.17 |
DisclosureSEC source: 0001209191-24-001537 · doc4.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 415,494 F1 · kind: The reported sale of 1,869 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023. F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. F4 · ownership.nature: Shares held directly by MGC 2018 LP. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 00:33 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0000899243-23-015307 · doc4.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:25 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 20,724 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018293 · doc4.xml · derivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,724 Underlying: Common Stock · 20,724 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries B Convertible Preferred Stock · Derivative | 71,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · derivative · entry 10 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 71,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries B Convertible Preferred Stock · Derivative | 61,491 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · derivative · entry 9 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 61,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries A Convertible Preferred Stock · Derivative | 333,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · derivative · entry 8 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 333,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries A Convertible Preferred Stock · Derivative | 285,156 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · derivative · entry 7 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 285,156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 82,618 | $15.00 | $1,239,270.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 6 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 487,592 F3 · ownership.nature: Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 70,716 | $15.00 | $1,060,740.00 |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 5 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 417,363 F2 · ownership.nature: Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 71,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 4 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 404,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 61,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 3 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 346,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 333,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 2 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 333,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.nature: Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 285,156 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012991 · doc4.xml · nonDerivative · entry 1 Readnour Robin Shane · CIK 0001914883 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 285,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP"). F4 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.